Literature DB >> 10930996

p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome.

V Brito-Babapulle1, R Hamoudi, E Matutes, S Watson, P Kaczmarek, H Maljaie, D Catovsky.   

Abstract

In a series of 24 patients with chronic T-lymphoid disorders [13 T-prolymphocytic leukaemia (T-PLL) and 11 Sezary syndrome] we have studied (i) chromosome 17p abnormalities and p53 allele deletion by fluorescence in situ hybridization; (ii) mutation in the exons of the p53 gene by direct DNA sequencing; and (iii) p53 protein expression by immunocytochemistry and, in some cases, also by flow cytometry with DO-1, a monoclonal antibody to the p53 protein. The study revealed p53 deletion and accumulation of p53 protein in the absence of mutation in the exons that included the hot-spots and differs from that described in B-prolymphocytic leukaemia. Seven T-PLL and five Sezary syndrome patients had p53 overexpression, and five T-PLL and nine Sezary syndrome patients showed p53 deletion. Although the majority of cases with p53 accumulation had p53 deletion, the proportion of cells with the deletion did not correlate with the proportion of cells positive for p53 expression. Two cases of T-PLL showed strong p53 expression in the absence of p53 deletion, and one case of Sezary syndrome with p53 deletion in 97% of cells did not express p53. These findings suggest that a non-mutational mechanism exists for the accumulation of p53 protein in these T-cell disorders. The oncogenic effect of the accumulating wild-type protein has been reported in other malignancies. Whether haploidy resulting from p53 deletion contributes to this mechanism has yet to be determined. Alternatively, the frequent loss of the p53 gene could be associated with the deletion of an adjacent gene, which could be involved in the pathogenesis of these diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930996     DOI: 10.1046/j.1365-2141.2000.02174.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Authors:  E I Andersson; S Pützer; B Yadav; O Dufva; S Khan; L He; L Sellner; A Schrader; G Crispatzu; M Oleś; H Zhang; S Adnan-Awad; S Lagström; D Bellanger; J P Mpindi; S Eldfors; T Pemovska; P Pietarinen; A Lauhio; K Tomska; C Cuesta-Mateos; E Faber; S Koschmieder; T H Brümmendorf; S Kytölä; E-R Savolainen; T Siitonen; P Ellonen; O Kallioniemi; K Wennerberg; W Ding; M-H Stern; W Huber; S Anders; J Tang; T Aittokallio; T Zenz; M Herling; S Mustjoki
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

2.  p53 phosphorylation and TP53 copy-number alterations in chronic graft-versus-host oral lichen preceding squamous cell carcinoma.

Authors:  Maxime Battistella; Wendy Cuccuini; Morad Elbouchtaoui; Christophe Leboeuf; Louis-François Plassa; Fatiha Bouhidel; Arnaud Rigolet; Véronique Meignin; Gérard Socié; Philippe Ratajczak; Anne Janin
Journal:  J Invest Dermatol       Date:  2013-09-04       Impact factor: 8.551

3.  The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome.

Authors:  Ana Carolina da Silva Almeida; Francesco Abate; Hossein Khiabanian; Estela Martinez-Escala; Joan Guitart; Cornelis P Tensen; Maarten H Vermeer; Raul Rabadan; Adolfo Ferrando; Teresa Palomero
Journal:  Nat Genet       Date:  2015-11-09       Impact factor: 38.330

Review 4.  Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.

Authors:  Anna Orlova; Bettina Wingelhofer; Heidi A Neubauer; Barbara Maurer; Angelika Berger-Becvar; György Miklós Keserű; Patrick T Gunning; Peter Valent; Richard Moriggl
Journal:  Expert Opin Ther Targets       Date:  2017-11-24       Impact factor: 6.902

Review 5.  Mature T-Cell leukemias: Challenges in Diagnosis.

Authors:  Dima El-Sharkawi; Ayoma Attygalle; Claire Dearden
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.